Hua Xia Shi Bao·2025-09-05 09:44Core Viewpoint - The recent suspension of procurement qualifications for 28 commonly used clinical drugs in Shanghai due to non-compliance with price adjustment requirements reflects a broader national initiative aimed at regulating drug prices and ensuring fairness across provinces [2][3][9]. Group 1: Price Adjustment and Impact - The suspended drugs include essential items such as Banlangen Granules and Chuanxinlian Tablets, with notable companies like Taiji Group and Tianjin Tongrentang affected [2][3]. - The price adjustment initiative is part of a national strategy to eliminate price discrepancies between provinces, ensuring local prices do not exceed national monitoring levels [2][8]. - Previous price adjustments in Inner Mongolia for Banlangen Granules have set a precedent, indicating a coordinated effort across regions to enforce price compliance [7][9]. Group 2: Market Dynamics and Responses - The price adjustment has led to a complex dynamic where companies are reluctant to forfeit profit margins while also needing to comply with regulatory demands [7][9]. - Despite the procurement suspensions, there are no immediate concerns about clinical supply shortages, as there are numerous production batches available for the affected drugs [8]. - The price governance has expanded to include unselected drugs in national procurement, indicating a shift in regulatory focus [8][9]. Group 3: Regulatory Developments - The National Medical Insurance Administration has implemented various measures to monitor and control drug prices, including the use of big data and online price comparisons [10][9]. - The ongoing centralized procurement efforts have led to significant price reductions and increased competition among pharmaceutical companies [10][9]. - The regulatory landscape is evolving towards a more coordinated approach, although challenges remain in balancing regional cost variations and supply impacts [10].